Boostrix

BIOLOGICAL14 trials

Sponsors

Novartis Pharma AG, GlaxoSmithKline, Universiteit Antwerpen, University Hospital, Ghent

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesHerpes ZosterPertussisPrevention of Infections With Bordetella PertussisRelapsing multiple sclerosis (RMS)Respiratory Syncytial Virus Infections

Phase 2

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

CompletedNCT02360475

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2015-03-20End: 2016-06-21Updated: 2018-07-03

A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

CompletedNCT02676895

GlaxoSmithKlineShigella Sonnei Infection

Start: 2016-08-08End: 2017-03-10Updated: 2019-02-18

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

CompletedNCT02753413

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2016-04-01End: 2016-06-28Updated: 2018-06-26

Phase 3

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

CompletedNCT00406562

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2007-01-31End: 2007-02-28Target: 30Updated: 2016-10-27

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

CompletedNCT00452686

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2007-03-31End: 2007-05-31Target: 660Updated: 2016-10-28

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

CompletedNCT00489970

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2007-06-01End: 2016-03-01Updated: 2020-05-01

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

CompletedNCT01738477

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2013-01-31End: 2014-04-02Updated: 2018-06-06

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

CompletedNCT02052596

GlaxoSmithKlineHerpes Zoster

Start: 2014-02-07End: 2016-04-21Updated: 2018-04-24

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

CompletedNCT03311659

GlaxoSmithKlineDiphtheria-Tetanus-acellular Pertussis Vaccines

Start: 2018-01-26End: 2018-08-31Updated: 2020-10-27

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)

Active, not recruitingCTIS2023-507906-15-00

Novartis Pharma AGRelapsing multiple sclerosis (RMS)

Start: 2019-01-30Target: 963Updated: 2025-11-14

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)

Active, not recruitingCTIS2023-507906-15-00

Novartis Pharma AGRelapsing multiple sclerosis (RMS)

Start: 2019-01-30Target: 963Updated: 2025-11-14

Phase 4

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

TerminatedNCT00544271

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2003-05-31End: 2004-01-31Updated: 2016-09-07

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

CompletedNCT02408926

Universiteit AntwerpenPertussis

Start: 2015-04-30End: 2018-08-31Updated: 2019-10-24

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

CompletedNCT02555540

University Hospital, GhentPrevention of Infections With Bordetella Pertussis

Start: 2015-08-24End: 2016-12-15Updated: 2022-12-20

Unknown Phase

Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

CompletedNCT01929291

GlaxoSmithKlineDiphtheria-Tetanus-acellular Pertussis Vaccines

Start: 2013-09-23End: 2016-01-11Updated: 2019-09-25

Related Papers

The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines.

2025-10-22

Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months.

2024-09-20

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study

Vaccines2024-07-053 citations

Antibody persistence to diphtheria toxoid, tetanus toxoid, <i>Bordetella pertussis</i> antigens, and <i>Haemophilus influenzae</i> type b following primary and first booster with pentavalent versus hexavalent vaccines

Human Vaccines & Immunotherapeutics2024-05-166 citations

Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.

2024-02-287 citations

Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination

The Journal of Infectious Diseases2023-06-074 citations

Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study

Frontiers in Immunology2022-09-0921 citations

Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.

2022-02-054 citations

Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.

2020-09-0210 citations

Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.

2020-04-2110 citations

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

Human Vaccines & Immunotherapeutics2020-01-172 citations

The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.

2019-08-2016 citations

Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial

Clinical Infectious Diseases2019-08-1263 citations

A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea

Journal of Korean Medical Science2019-01-0110 citations

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.

2018-09-0710 citations

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Human Vaccines & Immunotherapeutics2018-04-0922 citations

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

2018-04-0134 citations

A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country

Frontiers in Immunology2017-12-22107 citations